糖尿病性ケトアシドーシス治療市場 - 世界の産業規模、シェア、動向、機会、予測：治療タイプ別、エンドユーザー別（病院、外来手術センター、在宅ケア）、地域別、競合、2020年～2030年

糖尿病性ケトアシドーシス治療の世界市場規模は2024年に40億8,000万米ドル、2030年には57億米ドルに達すると予測、CAGRは5.71%。

糖尿病性ケトアシドーシス（DKA）治療の世界市場は、糖尿病の負担が世界的に増加し続けていることから、著しい成長を遂げています。DKAは、コントロールされていない糖尿病から生じる重篤で生命を脅かす合併症であり、インスリン療法、点滴、電解質補充による早急な医療介入が必要です。患者の意識の高まりと診断能力の向上が相まって、この病態の認識と治療が迅速に行われるようになり、効果的な治療法の需要が高まっています。さらに、重症治療室の技術向上や、糖尿病関連合併症に特化した救急部門の増加も市場を支えています。製薬会社は、インスリンの高度な製剤や補助療法を開発するための研究に多額の投資を行っており、患者のより安全で迅速な回復を保証しています。

市場の成長促進要因としては、1型糖尿病と2型糖尿病の有病率の増加が挙げられ、これは新規診断患者と長期入院患者の両方におけるDKAリスクの上昇に直結します。急性高血糖による入院患者数の増加と、速効型インスリンや併用療法といった最新の治療オプションの利用可能性の増加が、市場の拡大を後押ししています。患者中心の治療が重視され、インスリン持続注入システムなどの革新的なドラッグデリバリー方法が開発され、治療成績が向上しています。ヘルスケア機関による教育プログラムは、DKA症状の早期発見を改善し、タイムリーな介入と死亡率の減少につながっています。さらに、糖尿病管理プログラムに対する政府支援の増加やヘルスケアインフラへの投資が市場成長に寄与しています。

市場を形成する動向には、臨床医が患者固有のニーズや併存疾患に基づいて治療をカスタマイズしようとする精密医療や個別化治療アプローチの採用が含まれます。モバイルアプリや遠隔モニタリングシステムなどのデジタルヘルスツールの統合により、患者の治療プロトコールへのアドヒアランスが向上し、緊急DKAイベントの頻度が減少しています。しかし、市場はその進展を遅らせる可能性のある課題に直面しています。未発達地域におけるDKAに関する認知度の低さ、高度な治療に伴うコストの高さ、訓練を受けたヘルスケア専門家の確保に関する懸念などが大きな障壁となっています。地域によっては、ヘルスケアインフラの不備による診断や治療の遅れがDKAに関連するリスクを悪化させています。このような障害にもかかわらず、継続的な技術革新、投資の増加、患者の安全性への関心の高まりが、今後数年間の世界糖尿病性ケトアシドーシス治療市場の着実な成長を支えていくと予想されます。

主な市場促進要因

世界の糖尿病有病率の上昇

主な市場課題

治療関連合併症の高いリスク

主要市場動向

在宅ケアと遠隔モニタリングの統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の糖尿病性ケトアシドーシス治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療タイプ別（水分補充療法、電解質補充療法、インスリン療法、その他）
  • エンドユーザー別（病院、外来手術センター（ASC）、在宅ケア施設）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の糖尿病性ケトアシドーシス治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の糖尿病性ケトアシドーシス治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の糖尿病性ケトアシドーシス治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の糖尿病性ケトアシドーシス治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの糖尿病性ケトアシドーシス治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Novo Nordisk AS
• Eli Lilly and Company
• Pfizer Inc.
• Baxter International Inc.
• B. Braun Melsungen AG
• Teva Pharmaceutical Industries Ltd.
• Fresenius Kabi
• ICU Medical, Inc.
• Hikma Pharmaceuticals
• Sanofi S.A.

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Diabetic Ketoacidosis Treatment Market was valued at USD 4.08 Billion in 2024 and is expected to reach USD 5.70 Billion by 2030 with a CAGR of 5.71%. The Global Diabetic Ketoacidosis (DKA) Treatment Market is witnessing significant growth as the burden of diabetes continues to rise worldwide. DKA is a serious and life-threatening complication that arises from uncontrolled diabetes, requiring immediate medical intervention with insulin therapy, intravenous fluids, and electrolyte replacement. Increasing patient awareness, coupled with better diagnostic capabilities, has resulted in faster recognition and treatment of this condition, boosting demand for effective therapies. The market is further supported by technological improvements in critical care units and a rising number of specialized emergency departments focusing on diabetes-related complications. Pharmaceutical companies are investing heavily in research to develop advanced formulations of insulin and adjunctive therapies, ensuring safer and quicker recovery for patients.

Growth drivers of the market include the increasing prevalence of type 1 and type 2 diabetes, which directly correlates with a higher risk of DKA among both newly diagnosed and long-term patients. Rising hospital admissions due to acute hyperglycemia, along with the growing availability of modern treatment options such as fast-acting insulin and combination therapies, are strengthening market expansion. Greater emphasis on patient-centric care and the development of innovative drug delivery methods, such as continuous insulin infusion systems, are enhancing treatment outcomes. Educational programs by healthcare institutions are improving early recognition of DKA symptoms, which leads to timely interventions and reduced mortality rates. Moreover, increasing government support for diabetes management programs and investments in healthcare infrastructure are contributing to market growth.

Trends shaping the market include the adoption of precision medicine and personalized treatment approaches, as clinicians seek to tailor therapies based on patient-specific needs and comorbidities. The integration of digital health tools, such as mobile apps and remote monitoring systems, is improving patient adherence to treatment protocols and reducing the frequency of emergency DKA events. However, the market faces certain challenges that may slow its progress. Limited awareness about DKA in underdeveloped regions, high costs associated with advanced treatments, and concerns over the availability of trained healthcare professionals are significant barriers. In some regions, delays in diagnosis and treatment due to inadequate healthcare infrastructure exacerbate the risks associated with DKA. Despite these obstacles, continuous innovations, increasing investments, and a rising focus on patient safety are expected to support steady growth of the Global Diabetic Ketoacidosis Treatment Market in the coming years.

Key Market Drivers

Rising Global Prevalence of Diabetes

The rising global prevalence of diabetes has emerged as a pivotal driver for the growth of the Global Diabetic Ketoacidosis (DKA) Treatment Market. Global data from the International Diabetes Federation (IDF) indicate that 589 million adults aged 20-79 were living with diabetes in 2024, roughly equating to one in nine people worldwide. This figure is projected to climb toward 853 million by 2050, indicating a substantial increase in the population at risk. Concurrently, the World Health Organization (WHO) reports a staggering rise from 200 million people with diabetes in 1990 to 830 million by 2022, with low- and middle-income countries most severely impacted.

This escalating diabetes burden directly contributes to a higher incidence of DKA, a life-threatening metabolic complication that arises from uncontrolled hyperglycemia and insulin deficiency. Insufficient disease management, delayed diagnosis, and poor glycemic control in many populations further elevate the risk of DKA episodes. Healthcare systems across the globe are consequently observing a growing influx of emergency admissions related to DKA, generating increased demand for rapid and effective treatment solutions such as insulin therapy, fluid resuscitation, and electrolyte replacement.

The expanding pool of diabetes patients is prompting hospitals, pharmaceutical companies, and healthcare providers to enhance diagnostic protocols, introduce more effective therapeutic regimens, and invest in educational programs to aid early detection of DKA symptoms. This holistic response from improved clinical infrastructure to enhanced patient awareness is aligned to reduce DKA-related morbidity and mortality, while driving sustained demand for treatment modalities.

Key Market Challenges

High Risk of Treatment-Related Complications

One of the most significant challenges faced by the Global Diabetic Ketoacidosis (DKA) Treatment Market is the high risk of treatment-related complications, which can impact patient outcomes and healthcare provider confidence. Insulin therapy, the cornerstone of DKA management, requires precise dosing and continuous monitoring to avoid serious adverse events. Inadequate or delayed insulin administration can result in hypoglycemia, which poses an immediate threat to patient safety and may lead to seizures, neurological damage, or even death. Simultaneously, aggressive fluid replacement, necessary to correct severe dehydration and restore electrolyte balance, carries risks such as fluid overload, pulmonary edema, or rapid shifts in potassium levels, potentially leading to cardiac arrhythmias. These complications necessitate the presence of skilled medical professionals and advanced monitoring equipment, which may not be available in all healthcare settings, particularly in low-resource or rural regions.

Treatment-related risks also increase the burden on healthcare systems, as managing complications requires extended hospital stays, intensive care resources, and additional interventions, escalating overall treatment costs. The fear of adverse events can sometimes delay initiation of therapy or discourage aggressive treatment approaches, further complicating patient recovery. Training programs for physicians, nurses, and emergency care personnel are critical for minimizing these risks, yet gaps in standardized education and experience persist in several markets. The complexity of managing DKA safely underscores the need for improved clinical protocols, safer insulin formulations, and optimized fluid replacement strategies. Until such measures are widely implemented, the high risk of treatment-related complications will remain a major barrier affecting market growth, influencing healthcare provider adoption, and shaping investment in innovative solutions designed to enhance safety and patient outcomes in DKA management.

Key Market Trends

Integration of Home-Based Care and Remote Monitoring

The Global Diabetic Ketoacidosis (DKA) Treatment Market is witnessing a significant trend toward the integration of home-based care and remote monitoring, driven by the increasing demand for patient-centric and convenient healthcare solutions. With advancements in technology, continuous glucose monitoring (CGM) systems and wearable insulin pumps are enabling patients and caregivers to track blood glucose levels in real time, allowing for timely interventions that prevent the onset or escalation of DKA episodes. Remote monitoring platforms facilitate constant communication between patients and healthcare providers, allowing clinicians to adjust insulin dosing, recommend dietary modifications, or advise on fluid and electrolyte management without the patient needing to visit a hospital. This approach reduces the strain on emergency departments and intensive care units while minimizing hospitalization rates and associated costs.

The integration of digital health solutions is also improving adherence to treatment protocols, as patients receive reminders, alerts, and data-driven insights into their glycemic trends. Telemedicine consultations are increasingly being utilized for follow-up care, enabling physicians to identify early warning signs of DKA and intervene proactively. Home-based care combined with remote monitoring enhances the ability to manage high-risk populations, such as pediatric patients, elderly individuals, and those with comorbidities, who are more susceptible to severe DKA complications. Healthcare providers are increasingly adopting structured care pathways that leverage these technologies to improve outcomes, reduce recovery times, and optimize resource utilization. The convergence of homecare, remote monitoring, and predictive analytics is transforming DKA management from reactive hospital-based treatment to a proactive, continuous care model, making it one of the most influential trends shaping the market's future growth.

Key Market Players

• Novo Nordisk AS
• Eli Lilly and Company
• Pfizer Inc.
• Baxter International Inc.
• B. Braun Melsungen AG
• Teva Pharmaceutical Industries Ltd.
• Fresenius Kabi
• ICU Medical, Inc.
• Hikma Pharmaceuticals
• Sanofi S.A.

Report Scope:

In this report, the Global Diabetic Ketoacidosis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Ketoacidosis Treatment Market, By Treatment Type:

• Fluid Replacement Therapy
• Electrolyte Replacement Therapy
• Insulin Therapy
• Others

Diabetic Ketoacidosis Treatment Market, By End User:

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Homecare Settings

Diabetic Ketoacidosis Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Ketoacidosis Treatment Market.

Available Customizations:

Global Diabetic Ketoacidosis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Diabetic Ketoacidosis Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Fluid Replacement Therapy, Electrolyte Replacement Therapy, Insulin Therapy, Others)
  • 5.2.2. By End User (Hospitals, Ambulatory Surgical Centers (ASCs), Homecare Settings)
  • 5.2.3. By Company (2024)
  • 5.2.4. By Region
• 5.3. Market Map

6. North America Diabetic Ketoacidosis Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Diabetic Ketoacidosis Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Mexico Diabetic Ketoacidosis Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Canada Diabetic Ketoacidosis Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By End User

7. Europe Diabetic Ketoacidosis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Diabetic Ketoacidosis Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By End User
  • 7.3.2. Germany Diabetic Ketoacidosis Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By End User
  • 7.3.3. United Kingdom Diabetic Ketoacidosis Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy Diabetic Ketoacidosis Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Diabetic Ketoacidosis Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By End User

8. Asia-Pacific Diabetic Ketoacidosis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Diabetic Ketoacidosis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By End User
  • 8.3.2. India Diabetic Ketoacidosis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By End User
  • 8.3.3. South Korea Diabetic Ketoacidosis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By End User
  • 8.3.4. Japan Diabetic Ketoacidosis Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Diabetic Ketoacidosis Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By End User

9. South America Diabetic Ketoacidosis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Diabetic Ketoacidosis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Diabetic Ketoacidosis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Diabetic Ketoacidosis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By End User

10. Middle East and Africa Diabetic Ketoacidosis Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Diabetic Ketoacidosis Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Diabetic Ketoacidosis Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE Diabetic Ketoacidosis Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novo Nordisk AS
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Eli Lilly and Company
• 15.3. Pfizer Inc.
• 15.4. Baxter International Inc.
• 15.5. B. Braun Melsungen AG
• 15.6. Teva Pharmaceutical Industries Ltd.
• 15.7. Fresenius Kabi
• 15.8. ICU Medical, Inc.
• 15.9. Hikma Pharmaceuticals
• 15.10. Sanofi S.A.

16. Strategic Recommendations

17. About Us & Disclaimer